Medicenna Therapeutics Corp. MDNA
Set alert
0.16 +0.16 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
News
5 days ago globenewswire.com
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and…